Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?

Authors: Nina Bassarak, Thomas Blankenstein, Ansgar Brüning, Darius Dian, Florian Bergauer, Klaus Friese, Ioannis Mylonas

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

During surgery for endometrial cancer, a pelvic lymphadenectomy with or without para-aortic lymphadenectomy is performed at least in patients with risk factors (stage I, grading 2 and/or histological subtypes with higher risk of lymphatic spread), and is hence recommended by the International Federation of Obstetrics and Gynecology (FIGO). Although lymph node metastases are important prognostic parameters, it has been contentious whether a pelvic lymph node dissection itself has a prognostic impact in the treatment of endometrial cancer, especially in endometrioid adenocarcinoma. Therefore, this study evaluated whether lymphadenectomy has a prognostic impact in patients with endometrioid adenocarcinoma.

Methods

The benefits of lymphadenectomy were examined in 214 patients with a histological diagnosis of endometrial adenocarcinoma. Tumour characteristics were analysed with respect to the surgical and pathological stage.

Results

Of the 214 patients with endometrial adenocarcinoma, 171 (79.9%) were classified as FIGO stage I, 15 (7.0%) FIGO stage II, 21 (9.8%) FIGO stage III and 7 (3.3%) FIGO stage IV. One hundred and thirty four (62.6%) of the patients had a histological grade 1 tumour, while 56 (26.2%) and 24 (11.2%) had a histological grade 2 or grade 3 tumour, respectively. Lymphadenectomy was performed in 151 (70.6%) patients. Only 11 (5.1%) patients showed metastatic disease in the lymph nodes. The performance of a lymphadenectomy resulted in significantly increased cause-specific and overall survival, while progression-free survival was not affected by this operative procedure.

Conclusions

The performance of an operative lymphadenectomy resulted in better survival of patients with endometrioid adenocarcinoma. This increase was significant for cause-specific and overall survival, while there was a tendency only towards increased progression-free survival. Therefore, even in endometrioid adenocarcinoma, a pelvic and/or para-aortic lymphadenectomy should be performed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin. 2004, 54 (1): 8-29. 10.3322/canjclin.54.1.8.CrossRefPubMed Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin. 2004, 54 (1): 8-29. 10.3322/canjclin.54.1.8.CrossRefPubMed
2.
go back to reference Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK: Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003, 8 (6): 541-552. 10.1634/theoncologist.8-6-541.CrossRefPubMed Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK: Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003, 8 (6): 541-552. 10.1634/theoncologist.8-6-541.CrossRefPubMed
3.
go back to reference FIGO stages (announcements). Gynecol Oncol. 1989, 35: 125-127. 10.1016/0090-8258(89)90027-9. FIGO stages (announcements). Gynecol Oncol. 1989, 35: 125-127. 10.1016/0090-8258(89)90027-9.
4.
go back to reference Sehouli J, Camara O, Stengel D, Kohler G, Lichtenegger W: Multi-institutional survey on the value of lymphadenectomy in endometrial carcinoma in Germany. Gynakol Geburtshilfliche Rundsch. 2003, 43 (2): 104-110. 10.1159/000069163.CrossRefPubMed Sehouli J, Camara O, Stengel D, Kohler G, Lichtenegger W: Multi-institutional survey on the value of lymphadenectomy in endometrial carcinoma in Germany. Gynakol Geburtshilfliche Rundsch. 2003, 43 (2): 104-110. 10.1159/000069163.CrossRefPubMed
5.
go back to reference Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE: Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991, 40 (1): 55-65. 10.1016/0090-8258(91)90086-K.CrossRefPubMed Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE: Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991, 40 (1): 55-65. 10.1016/0090-8258(91)90086-K.CrossRefPubMed
6.
go back to reference Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB: Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987, 60 (8 Suppl): 2035-2041.CrossRefPubMed Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB: Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987, 60 (8 Suppl): 2035-2041.CrossRefPubMed
7.
go back to reference Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F, Conner W: Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol. 1995, 56 (1): 29-33. 10.1006/gyno.1995.1005.CrossRefPubMed Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F, Conner W: Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol. 1995, 56 (1): 29-33. 10.1006/gyno.1995.1005.CrossRefPubMed
8.
go back to reference Orr JW, Holimon JL, Orr PF: Stage I corpus cancer: is teletherapy necessary?. Am J Obstet Gynecol. 1997, 176 (4): 777-788. 10.1016/S0002-9378(97)70601-X. discussion 788-779CrossRefPubMed Orr JW, Holimon JL, Orr PF: Stage I corpus cancer: is teletherapy necessary?. Am J Obstet Gynecol. 1997, 176 (4): 777-788. 10.1016/S0002-9378(97)70601-X. discussion 788-779CrossRefPubMed
9.
go back to reference Ceccaroni M, Savelli L, Bovicelli A, Alboni C, Ceccarini M, Farina A, Bovicelli L: Prognostic value of pelvic lymphadenectomy in surgical treatment of apparent stage I endometrial cancer. Anticancer Res. 2004, 24 (3b): 2073-2078.PubMed Ceccaroni M, Savelli L, Bovicelli A, Alboni C, Ceccarini M, Farina A, Bovicelli L: Prognostic value of pelvic lymphadenectomy in surgical treatment of apparent stage I endometrial cancer. Anticancer Res. 2004, 24 (3b): 2073-2078.PubMed
10.
go back to reference Abu-Rustum NR, Iasonos A, Zhou Q, Oke E, Soslow RA, Alektiar KM, Chi DS, Barakat RR: Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?. Am J Obstet Gynecol. 2008, 198 (4): e451-455. discussion 457 e455-456CrossRef Abu-Rustum NR, Iasonos A, Zhou Q, Oke E, Soslow RA, Alektiar KM, Chi DS, Barakat RR: Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?. Am J Obstet Gynecol. 2008, 198 (4): e451-455. discussion 457 e455-456CrossRef
11.
go back to reference Lutman CV, Havrilesky LJ, Cragun JM, Secord AA, Calingaert B, Berchuck A, Clarke-Pearson DL, Soper JT: Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol. 2006, 102 (1): 92-97. 10.1016/j.ygyno.2005.11.032.CrossRefPubMed Lutman CV, Havrilesky LJ, Cragun JM, Secord AA, Calingaert B, Berchuck A, Clarke-Pearson DL, Soper JT: Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol. 2006, 102 (1): 92-97. 10.1016/j.ygyno.2005.11.032.CrossRefPubMed
12.
go back to reference Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A: Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005, 23 (16): 3668-3675. 10.1200/JCO.2005.04.144.CrossRefPubMed Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A: Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005, 23 (16): 3668-3675. 10.1200/JCO.2005.04.144.CrossRefPubMed
13.
go back to reference Smith DC, Macdonald OK, Lee CM, Gaffney DK: Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis. Int J Gynecol Cancer. 2008, 18 (2): 255-261. 10.1111/j.1525-1438.2007.01020.x.CrossRefPubMed Smith DC, Macdonald OK, Lee CM, Gaffney DK: Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis. Int J Gynecol Cancer. 2008, 18 (2): 255-261. 10.1111/j.1525-1438.2007.01020.x.CrossRefPubMed
14.
go back to reference Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK: Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009, 373 (9658): 125-136. 10.1016/S0140-6736(08)61766-3.CrossRefPubMed Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK: Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009, 373 (9658): 125-136. 10.1016/S0140-6736(08)61766-3.CrossRefPubMed
15.
go back to reference Prat J: Prognostic parameters of endometrial carcinoma. Hum Pathol. 2004, 35 (6): 649-662. 10.1016/j.humpath.2004.02.007.CrossRefPubMed Prat J: Prognostic parameters of endometrial carcinoma. Hum Pathol. 2004, 35 (6): 649-662. 10.1016/j.humpath.2004.02.007.CrossRefPubMed
16.
go back to reference Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, Jeschke U, Friese K, Mylonas I: Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer. 2007, 43 (16): 2434-2444. 10.1016/j.ejca.2007.08.014.CrossRefPubMed Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, Jeschke U, Friese K, Mylonas I: Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer. 2007, 43 (16): 2434-2444. 10.1016/j.ejca.2007.08.014.CrossRefPubMed
17.
go back to reference Mylonas I, Worbs S, Shabani N, Kuhn C, Kunze S, Schulze S, Dian D, Gingelmaier A, Schindlbeck C, Bruning A, Sommer H, Jeschke U, Friese K: Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur J Cancer. 2009, 45 (7): 1304-1314. 10.1016/j.ejca.2009.01.008.CrossRefPubMed Mylonas I, Worbs S, Shabani N, Kuhn C, Kunze S, Schulze S, Dian D, Gingelmaier A, Schindlbeck C, Bruning A, Sommer H, Jeschke U, Friese K: Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur J Cancer. 2009, 45 (7): 1304-1314. 10.1016/j.ejca.2009.01.008.CrossRefPubMed
18.
go back to reference Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.2307/2281868.CrossRef Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.2307/2281868.CrossRef
19.
go back to reference Cox DR: Regression models and life tables. J R Stat Soc B. 1972, 34: 187-220. Cox DR: Regression models and life tables. J R Stat Soc B. 1972, 34: 187-220.
20.
go back to reference Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S: Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006, 95 (Suppl 1): S105-143. 10.1016/S0020-7292(06)60031-3.CrossRefPubMed Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S: Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006, 95 (Suppl 1): S105-143. 10.1016/S0020-7292(06)60031-3.CrossRefPubMed
21.
go back to reference Dallenbach-Hellweg G: Histopathologie und Stadieneinteilung des Endometriumkarzinoms inklusive seiner Präkanzerosen. Onkologe. 1999, 5: 388-395. 10.1007/s007610050373.CrossRef Dallenbach-Hellweg G: Histopathologie und Stadieneinteilung des Endometriumkarzinoms inklusive seiner Präkanzerosen. Onkologe. 1999, 5: 388-395. 10.1007/s007610050373.CrossRef
22.
go back to reference Barakat RR, Lev G, Hummer AJ, Sonoda Y, Chi DS, Alektiar KM, Abu-Rustum NR: Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches. Gynecol Oncol. 2007, 105 (1): 150-156. 10.1016/j.ygyno.2006.11.007.CrossRefPubMed Barakat RR, Lev G, Hummer AJ, Sonoda Y, Chi DS, Alektiar KM, Abu-Rustum NR: Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches. Gynecol Oncol. 2007, 105 (1): 150-156. 10.1016/j.ygyno.2006.11.007.CrossRefPubMed
23.
go back to reference Yabushita H, Shimazu M, Yamada H, Sawaguchi K, Noguchi M, Nakanishi M, Kawai M: Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in node-negative endometrial cancer. Gynecol Oncol. 2001, 80 (2): 139-144. 10.1006/gyno.2000.6067.CrossRefPubMed Yabushita H, Shimazu M, Yamada H, Sawaguchi K, Noguchi M, Nakanishi M, Kawai M: Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in node-negative endometrial cancer. Gynecol Oncol. 2001, 80 (2): 139-144. 10.1006/gyno.2000.6067.CrossRefPubMed
24.
go back to reference Gonzalez Bosquet J, Keeney GL, Mariani A, Webb MJ, Cliby WA: Cytokeratin staining of resected lymph nodes may improve the sensitivity of surgical staging for endometrial cancer. Gynecol Oncol. 2003, 91 (3): 518-525. 10.1016/j.ygyno.2003.08.026.CrossRefPubMed Gonzalez Bosquet J, Keeney GL, Mariani A, Webb MJ, Cliby WA: Cytokeratin staining of resected lymph nodes may improve the sensitivity of surgical staging for endometrial cancer. Gynecol Oncol. 2003, 91 (3): 518-525. 10.1016/j.ygyno.2003.08.026.CrossRefPubMed
25.
go back to reference Chang SJ, Kim WY, Yoon JH, Yoo SC, Chang KH, Ryu HS: Para-aortic lymphadenectomy improves survival in patients with intermediate to high-risk endometrial carcinoma. Acta Obstet Gynecol Scand. 2008, 87 (12): 1361-1369. 10.1080/00016340802503054.CrossRefPubMed Chang SJ, Kim WY, Yoon JH, Yoo SC, Chang KH, Ryu HS: Para-aortic lymphadenectomy improves survival in patients with intermediate to high-risk endometrial carcinoma. Acta Obstet Gynecol Scand. 2008, 87 (12): 1361-1369. 10.1080/00016340802503054.CrossRefPubMed
Metadata
Title
Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?
Authors
Nina Bassarak
Thomas Blankenstein
Ansgar Brüning
Darius Dian
Florian Bergauer
Klaus Friese
Ioannis Mylonas
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-224

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine